Skip to main content
AAN.com

Abstract

Background: Cognitive abilities of older persons range from normal, to mild cognitive impairment, to dementia. Few large longitudinal studies have compared the natural history of mild cognitive impairment with similar persons without cognitive impairment.
Methods: Participants were older Catholic clergy without dementia, 211 with mild cognitive impairment and 587 without cognitive impairment, who underwent annual clinical evaluation for AD and an assessment of different cognitive abilities. Cognitive performance tests were summarized to yield a composite measure of global cognitive function and separate summary measures of episodic memory, semantic memory, working memory, perceptual speed, and visuospatial ability. The authors compared the risk of death, risk of incident AD, and rates of change in global cognition and different cognitive domains among persons with mild cognitive impairment to those without cognitive impairment. All models controlled for age, sex, and education.
Results: On average, persons with mild cognitive impairment had significantly lower scores at baseline in all cognitive domains. Over an average of 4.5 years of follow-up, 30% of persons with mild cognitive impairment died, a rate 1.7 times higher than those without cognitive impairment (95% CI, 1.2 to 2.5). In addition, 64 (34%) persons with mild cognitive impairment developed AD, a rate 3.1 times higher than those without cognitive impairment (95% CI, 2.1 to 4.5). Finally, persons with mild cognitive impairment declined significantly faster on measures of episodic memory, semantic memory, and perceptual speed, but not on measures of working memory or visuospatial ability, as compared with persons without cognitive impairment.
Conclusions: Mild cognitive impairment is associated with an increased risk of death and incident AD, and a greater rate of decline in selected cognitive abilities.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology . 2001; 56: 1133–1142.
2.
Milwain E. Mild cognitive impairment: further caution. Lancet . 2000; 355: 1018.
3.
Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet . 2000; 355: 225–228.
4.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol . 1999; 56: 303–308.
5.
Morris JC, Storandt M, Miller P, et al. Mild cognitive impairment represents early-stage Alzheimer’s disease. Arch Neurol . 2001; 58: 397–405.
6.
Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol . 2001; 58: 411–416.
7.
Unverzagt FW, Gao S, Baiyewu O, et al. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology . 2001; 57: 1655–1662.
8.
Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet . 1997; 349: 1793–1796.
9.
Albert SM, Michaels K, Padilla M, et al. Functional significance of mild cognitive impairment in elderly patients without a dementia diagnosis. Am J Geriatr Psychiatry . 1999; 7: 213–220.
10.
Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology . 1989; 39: 1159–1165.
11.
Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses’ ratings of parkinsonian signs with a modified Unified Parkinson’s Disease Rating Scale. Neurology . 1997; 49: 1580–1587.
12.
Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex beta amyloid load in individuals with mild cognitive impairment. Exp Neurol . 1999; 158: 469–490.
13.
Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol . 2001; 49: 202–213.
14.
Mitchell TW, Nissanov J, Han LY, et al. Novel method to quantify neuropil threads in brains form elders with and without cognitive impairment. J Histochem Cytochem . 2000; 48: 1627–1637.
15.
Chu YP, Cochran EJ, Bennett DA, Mufson EJ, Kordower JH. Down regulation of TrkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and early Alzheimer’s disease. J Comp Neurol . 2001; 437: 296–307.
16.
Mufson EJ, Ma SY, Cochran EJ, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer’s disease. J Comp Neurol . 2000; 427: 19–30.
17.
DeKosky ST, Ikonomovic M, Styren S, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol . 2002; 51: 145–155.
18.
Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment and early Alzheimer’s disease. Ann Neurol . 2002; 51: 182–189.
19.
McKhann G, Drachmann D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer’s disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology . 1984; 34: 939.
20.
Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer’s disease. Arch Neurol . 2001; 58: 1395–1402.
21.
Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the mental state of patients for the clinician. J Psychiatr Res l975;l2:l89–l98.
22.
Wilson RS, Beckett LA, Barnes LL, et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002 (in press).
23.
Wilson RS, Mendes de Leon CF, Barnes LL, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer’s disease. JAMA . 2002; 287: 742–748.
24.
Wilson RS, Schneider JA, Barnes LL, et al. Effect of apolipoprotein E ε4 allele status on decline in different cognitive systems and development of Alzheimer’s disease over a 6-year period. Arch Neurol 2002 (in press).
25.
Welsh K, Butters N, Hughes JP, et al. Detection and staging of dementia in Alzheimer’s disease: use of the neuropsychological measures developed for CERAD. Arch Neurol . 1992; 49: 448–452.
26.
Albert MS, Smith LA, Scherr PA, et al. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer’s disease. Int J Neurosci . 1991; 57: 167–178.
27.
Wechsler D. Wechsler Memory Scale–Revised manual. New York: Psychological Corporation, 1987.
28.
Ekstrom RB, French JW, Harman HH, Dermen D. Manual for kit of factor-referenced cognitive tests. Princeton, NJ: Educational Testing Service, 1976.
29.
Blair JR, Spreen O. Predicting premorbid IQ: a revision of the National Adult Reading Test. Clin Neuropsychologist . 1989; 3: 129–136.
30.
Goodglass H, Kaplan E. The assessment of aphasia and related disorders. Philadelphia: Lea & Febiger, 1972.
31.
Nelson HE. National Adult Reading Test (NART): test manual. Windsor, UK: NFER Nelson, 1982.
32.
Cooper JA, Sagar HJ. Incidental and intentional recall in Parkinson’s disease: an account based on diminished attentional resources. J Clin Exp Neuropsychol . 1993; 15: 713–731.
33.
Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson’s disease and its relationship to motor disability. Brain . 1991; 114: 2095–2122.
34.
Craik F. A functional account of age differences in memory. In: Klix, Hagendorf H, eds. Human memory and cognitive capabilities: mechanisms and performances. Amsterdam: Elsevier Science Publishers BV, 1986: 409–422.
35.
Smith A. Symbol Digit Modalities Test manual–revised. Los Angeles: Western Psychological, 1984.
36.
Benton AL, Varney N, et al. Visuospatial judgment: a clinical test. Arch Neurol . 1978; 35: 364–367.
37.
Raven JC, Court JH, Raven J. Standard progressive matrices, 1992 edition; Raven manual: Section 3. Oxford: Oxford Psychologists Press, 1992.
38.
Beckett LA, Wilson RS, Bennett DA, Morris MC. Around the WORLD backward: an algorithm for scoring the MMSE WORLD item. Neurology . 1997; 48: 1733–1734.
39.
SAS Institute. SAS/STAT software. Changes and enhancements through release. Version 6.12. Cary, NC: SAS Institute, 1997.
40.
Wilson RS, Beckett LA, Bennett DA, Albert M, Evans DA. Change in cognitive function among older persons from a community population: relation to age and Alzheimer’s disease. Arch Neurol . 1999; 56: 1274–1279.
41.
Wilson RS, Gilley DW, Bennett DA, Beckett LA, Evans DA. Person-specific paths of cognitive decline in Alzheimer’s disease and their relation to age. Psychol Aging . 2000; 15: 18–28.
42.
Cox DR. Regression models and life-tables. J R Stat Soc [B] . 1972; 34: 187–220.
43.
Scarmeas N, Levy G, Tang MX, Manly J, Stern Y. Influence of leisure activity on the incidence of Alzheimer’s disease. Neurology . 2001; 57: 2236–2242.
44.
Laird N, Ware J. Random-effects models for longitudinal data. Biometrics . 1982; 38: 1963–1974.
45.
Gussekloo J, Westendorp RGJ, Remarque EJ, Lagaay AM, Heeren TJ, Knook DL. Impact of mild cognitive impairment on survival in very elderly people: cohort study. BMJ . 1997; 315: 1053–1054.
46.
Frisoni GB, Fratiglioni L, Fastbom J, Viitanene M, Winblad B. Mortality in nondemented subjects with cognitive impairment: the influence of health-related factors. Am J Epidemiol . 1999; 150: 1031–1044.
47.
Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer’s disease in memory-impaired patients: a prospective longitudinal study. Neurology . 1996; 46: 661–665.
48.
Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology . 1991; 41: 1006–1009.
49.
Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc . 1997; 45: 321–328.
50.
Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol . 2000; 57: 675–680.
51.
Bowen J, Teri L, Kukull W, McCormick W, McCurry SM, Larson EB. Progression to dementia in patients with isolated memory loss. Lancet . 1997; 349: 763–765.
52.
Goldman WP, Price JL, Storandt M, et al. Absence of cognitive impairment or decline in preclinical Alzheimer’s disease. Neurology . 2001; 56: 361–367.
53.
Bäckman L, Small BJ, Fratiglinoi L. Stability of the preclinical episodic memory deficit in Alzheimer’s disease. Brain . 2001; 124: 96–102.

Information & Authors

Information

Published In

Neurology®
Volume 59Number 2July 23, 2002
Pages: 198-205
PubMed: 12136057

Publication History

Received: November 27, 2001
Accepted: March 20, 2002
Published online: July 23, 2002
Published in print: July 23, 2002

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

D. A. Bennett, MD
From the Rush Alzheimer’s Disease Center and Rush Institute for Healthy Aging (Drs. Bennett, Wilson, Schneider, Evans, Aggarwal, Barnes, Fox, and J. Bach), and Departments of Neurological Sciences (Drs. Bennett, Wilson, Schneider, Evans, Barnes, Aggarwal, and Fox), Pathology (Dr. Schneider), and Internal Medicine (Dr. Evans), Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL; and Department of Epidemiology and Preventive Medicine (Dr. Beckett), School of Medicine, University of California at Davis.
R. S. Wilson, PhD
From the Rush Alzheimer’s Disease Center and Rush Institute for Healthy Aging (Drs. Bennett, Wilson, Schneider, Evans, Aggarwal, Barnes, Fox, and J. Bach), and Departments of Neurological Sciences (Drs. Bennett, Wilson, Schneider, Evans, Barnes, Aggarwal, and Fox), Pathology (Dr. Schneider), and Internal Medicine (Dr. Evans), Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL; and Department of Epidemiology and Preventive Medicine (Dr. Beckett), School of Medicine, University of California at Davis.
J. A. Schneider, MD
From the Rush Alzheimer’s Disease Center and Rush Institute for Healthy Aging (Drs. Bennett, Wilson, Schneider, Evans, Aggarwal, Barnes, Fox, and J. Bach), and Departments of Neurological Sciences (Drs. Bennett, Wilson, Schneider, Evans, Barnes, Aggarwal, and Fox), Pathology (Dr. Schneider), and Internal Medicine (Dr. Evans), Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL; and Department of Epidemiology and Preventive Medicine (Dr. Beckett), School of Medicine, University of California at Davis.
D. A. Evans, MD
From the Rush Alzheimer’s Disease Center and Rush Institute for Healthy Aging (Drs. Bennett, Wilson, Schneider, Evans, Aggarwal, Barnes, Fox, and J. Bach), and Departments of Neurological Sciences (Drs. Bennett, Wilson, Schneider, Evans, Barnes, Aggarwal, and Fox), Pathology (Dr. Schneider), and Internal Medicine (Dr. Evans), Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL; and Department of Epidemiology and Preventive Medicine (Dr. Beckett), School of Medicine, University of California at Davis.
L. A. Beckett, PhD
From the Rush Alzheimer’s Disease Center and Rush Institute for Healthy Aging (Drs. Bennett, Wilson, Schneider, Evans, Aggarwal, Barnes, Fox, and J. Bach), and Departments of Neurological Sciences (Drs. Bennett, Wilson, Schneider, Evans, Barnes, Aggarwal, and Fox), Pathology (Dr. Schneider), and Internal Medicine (Dr. Evans), Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL; and Department of Epidemiology and Preventive Medicine (Dr. Beckett), School of Medicine, University of California at Davis.
N. T. Aggarwal, MD
From the Rush Alzheimer’s Disease Center and Rush Institute for Healthy Aging (Drs. Bennett, Wilson, Schneider, Evans, Aggarwal, Barnes, Fox, and J. Bach), and Departments of Neurological Sciences (Drs. Bennett, Wilson, Schneider, Evans, Barnes, Aggarwal, and Fox), Pathology (Dr. Schneider), and Internal Medicine (Dr. Evans), Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL; and Department of Epidemiology and Preventive Medicine (Dr. Beckett), School of Medicine, University of California at Davis.
L. L. Barnes, PhD
From the Rush Alzheimer’s Disease Center and Rush Institute for Healthy Aging (Drs. Bennett, Wilson, Schneider, Evans, Aggarwal, Barnes, Fox, and J. Bach), and Departments of Neurological Sciences (Drs. Bennett, Wilson, Schneider, Evans, Barnes, Aggarwal, and Fox), Pathology (Dr. Schneider), and Internal Medicine (Dr. Evans), Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL; and Department of Epidemiology and Preventive Medicine (Dr. Beckett), School of Medicine, University of California at Davis.
J. H. Fox, MD
From the Rush Alzheimer’s Disease Center and Rush Institute for Healthy Aging (Drs. Bennett, Wilson, Schneider, Evans, Aggarwal, Barnes, Fox, and J. Bach), and Departments of Neurological Sciences (Drs. Bennett, Wilson, Schneider, Evans, Barnes, Aggarwal, and Fox), Pathology (Dr. Schneider), and Internal Medicine (Dr. Evans), Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL; and Department of Epidemiology and Preventive Medicine (Dr. Beckett), School of Medicine, University of California at Davis.
J. Bach, MSW
From the Rush Alzheimer’s Disease Center and Rush Institute for Healthy Aging (Drs. Bennett, Wilson, Schneider, Evans, Aggarwal, Barnes, Fox, and J. Bach), and Departments of Neurological Sciences (Drs. Bennett, Wilson, Schneider, Evans, Barnes, Aggarwal, and Fox), Pathology (Dr. Schneider), and Internal Medicine (Dr. Evans), Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL; and Department of Epidemiology and Preventive Medicine (Dr. Beckett), School of Medicine, University of California at Davis.

Notes

Address correspondence and reprint requests to Dr. David A. Bennett, Rush Alzheimer’s Disease Center, 1645 W. Jackson, Suite 675, Chicago, IL 60612; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Development and Validation of the Communities Geriatric Mild Cognitive Impairment Risk Calculator (CGMCI-Risk), Healthcare, 12, 20, (2015), (2024).https://doi.org/10.3390/healthcare12202015
    Crossref
  2. CD33 and SHP-1/PTPN6 Interaction in Alzheimer’s Disease, Genes, 15, 9, (1204), (2024).https://doi.org/10.3390/genes15091204
    Crossref
  3. Brain and serum lipidomic profiles implicate Lands cycle acyl chain remodeling association with APOEε4 and mild cognitive impairment, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1419253
    Crossref
  4. Periphery Biomarkers Predicting Conversion of Type 2 Diabetes to Pre-Alzheimer-Like Cognitive Decline: A Multicenter Follow-Up Study, Journal of Alzheimer's Disease, 100, s1, (S115-S129), (2024).https://doi.org/10.3233/JAD-240455
    Crossref
  5. Sparse Asymmetry in Locus Coeruleus Pathology in Alzheimer’s Disease, Journal of Alzheimer's Disease, 99, 1, (105-111), (2024).https://doi.org/10.3233/JAD-231328
    Crossref
  6. Disparities in Access to Diagnostic Evaluation for Alzheimer’s Disease in Individuals Dually Eligible for Medicare and Medicaid: A Modeling Study, Journal of Alzheimer's Disease, 98, 4, (1403-1414), (2024).https://doi.org/10.3233/JAD-231134
    Crossref
  7. Somatic nuclear mitochondrial DNA insertions are prevalent in the human brain and accumulate over time in fibroblasts, PLOS Biology, 22, 8, (e3002723), (2024).https://doi.org/10.1371/journal.pbio.3002723
    Crossref
  8. Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease, Alzheimer's Research & Therapy, 16, 1, (2024).https://doi.org/10.1186/s13195-024-01558-w
    Crossref
  9. Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS), Alzheimer's Research & Therapy, 16, 1, (2024).https://doi.org/10.1186/s13195-024-01458-z
    Crossref
  10. Identification of a specific APOE transcript and functional elements associated with Alzheimer’s disease, Molecular Neurodegeneration, 19, 1, (2024).https://doi.org/10.1186/s13024-024-00751-7
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share